If a data manager generated no additional manual queries on data in an EDC system and the data were deemed clean, why could the data appear to be not clean during the next review?
Answer(s): A
In an Electronic Data Capture (EDC) system, even after a data manager completes all manual queries and marks data as "clean," the data may later appear unclean if the site (study coordinator) makes subsequent updates in the system after re-reviewing the source documents. According to the Good Clinical Data Management Practices (GCDMP, Chapter: Electronic Data Capture Systems), site users maintain the authority to modify data entries as long as the system remains open for data entry. The EDC system audit trail captures such changes, which can automatically invalidate prior data reviews, triggering new discrepancies or changing system edit- check statuses.This situation commonly occurs when the site identifies corrections in the source (e.g., wrong date or lab result) and updates the EDC form accordingly. These post-cleaning changes require additional review cycles to ensure the database reflects accurate and verified information before final lock. Options B, C, and D are incorrect -- CRAs and medical monitors cannot directly change EDC data; they can only raise queries or request updates.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture Systems, Section 6.3 Post-Cleaning Data Changes and Audit Trails ICH E6 (R2) GCP, Section 5.5.3 Data Integrity and Change Control FDA 21 CFR Part 11 Electronic Records: Change Documentation Requirements
A study budgeted forty hours allocated over the three months following first protocol draft for Data Management Plan (DMP) creation. If there is a problem with this approach, what is it?
The main issue with this approach is that no time has been allocated for ongoing maintenance and updates of the Data Management Plan (DMP) throughout the study lifecycle. According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the DMP is a living document -- it must be continuously maintained and updated as study procedures evolve, particularly after protocol amendments, database modifications, or changes in data validation or reconciliation procedures.Budgeting only for initial creation (forty hours) over three months ignores the substantial effort required for DMP version control, stakeholder communication, and mid-study updates. These updates are mandatory to maintain compliance with ICH E6 (R2) GCP Section 5.5.3, which requires that all procedural documentation accurately reflect current practices. Thus, the problem is not the time allocated for creation but the lack of planning for ongoing maintenance.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Plan (DMP), Section 5.3 DMP Maintenance and Version ControlICH E6 (R2) Good Clinical Practice, Section 5.5.3 Documentation of Data Handling Procedures FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations Section on Documentation Updates
Based on the project Gantt chart as of 01 Nov 2019, an interim analysis is scheduled to occur early Q2 of 2020. All of the following are valid for initially assessing the status of data cleanliness EXCEPT:
Answer(s): C
When initially assessing data cleanliness in preparation for an interim analysis, the focus should be on outstanding issues that could affect data completeness and reliability. According to the GCDMP (Chapter: Data Quality Assurance and Control), key indicators of readiness include:The CRF data entry status of received pages (option A) to confirm completeness. Identification of missing pages or visits (option B) to verify subject-level completeness. A listing of outstanding discrepancies and their aging (option D) to assess unresolved data issues. Counting the number of discrepancies resolved to date (option C), however, does not reflect data quality or current data readiness--it indicates past actions rather than current unresolved risks. Therefore, it is not a valid measure for assessing interim data cleanliness.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 6.1 Data Readiness Assessments for Analysis ICH E6 (R2) GCP, Section 5.18.4 Ongoing Data Quality Review FDA Guidance for Industry: Oversight of Clinical Investigations Risk-Based Monitoring, Section 7 Data Quality Indicators
Which of the following data verification checks would most likely be included in a manual or visual data review step?
Answer(s): B
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks. According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks--such as verifying adverse event treatments against concomitant medication records--require clinical judgment and contextual understanding.For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations Data Verification Principles
Which of the following ensures that the trials are conducted and the data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirement(s)?
Standard Operating Procedures (SOPs) are formal, controlled documents that define standardized processes to ensure clinical trials are conducted in compliance with Good Clinical Practice (GCP), the study protocol, and regulatory requirements (such as ICH and FDA). According to Good Clinical Data Management Practices (GCDMP) and ICH E6(R2) GCP, SOPs are fundamental to quality management systems. They describe how tasks are performed, ensuring consistency, accountability, and traceability across all studies and team members. Proper adherence to SOPs guarantees that data are accurately generated, documented, and reported in compliance with ethical and regulatory standards.Other options serve different purposes:SAP (B) defines statistical methodology, not compliance control. DMP (C) focuses on study-specific data handling, not organizational compliance. CRFs (D) are tools for data collection but do not enforce compliance by themselves.Therefore, option A (SOP) is correct.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Quality Management and Compliance, Section 5.1 Role of SOPs in Regulatory ComplianceICH E6(R2) GCP, Section 2.13 and 5.1.1 Quality Management Systems and SOP Requirements FDA 21 CFR Part 312.50 Sponsor Responsibilities and Compliance Systems
Post your Comments and Discuss SCDM CCDM exam prep with other Community members:
Our website is free, but we have to fight against AI bots and content theft. We're sorry for the inconvenience caused by these security measures. You can access the rest of the CCDM content, but please register or login to continue.